Triple Analysis: Melanoma Therapeutics, Antibodies and Vaccines in Oncology - Biologics Market Research

Triple Analysis: Melanoma Therapeutics, Antibodies and Vaccines in Oncology
Published Date: August 2006
Published By: BioSeeker Group AB
Page Count: 388
Order Code: R474-207
Price: $4554 PDF E-mail from Publisher
Executive Summary
In this triple analysis report BioSeeker Group has analyzed three major and intertwined areas of cancer R&D, Melanoma Therapeutics, Antibodies and Vaccines in Oncology, which are all subjects to an extensive number of innovative drug candidates. This extensive 380+ pages report compiles and analyzes in parallel the progress concerning drug development and competitive situation in the three mentioned key oncology areas. The report will not only provide a framework but also a careful identification and evaluation of drug candidates, technologies and competitors.
Melanoma drug development has and will continue to have a strong focus on target therapy such as vaccines, monoclonal antibodies, dendritic cells, and gene therapy. In recent years, immunologic strategies including tumor vaccine and adjuvant therapy with interferon-alfa have been attempted to improve survival of patients with more advanced malignant melanoma. Another emerging strategy in anticancer therapy is the targeting of chemotherapy resistance by overcoming the antiapoptosis mechanisms of cancer cells.
Melanoma Highlights:
Disease overview, including incidence, unmet needs, risk factors, screening and diagnosis.
Analysis of current treatment and key therapeutic strategies, including surgery, immunotherapy, vaccines and combination therapies.
Includes product profiles of key drugs by class.
Progress analysis of on more than 55 pipeline products, including emerging and hot pre-clinical data, discontinued projects, clinical trial information, commercial potential and limiting factors.
Competitive landscape analysis, including extensive lay-out of competitors with collaborations, licensing, M&A etc, major highlights, trends and company profiles on more than 50 of the most important companies in melanoma.
Among the targeted therapies for cancer, immunotherapy is probably the most versatile treatment strategy for the eradication of tumors, metastatic spread or not. Main strategies of cancer immunotherapy aim at exploiting the therapeutic potential of tumor-specific antibodies and cellular immune effector mechanisms (vaccines).
Immunotherapy in Oncology Highlights:
In-depth competitive landscape assessment of the cancer immunotherapy market place; Including more than 200 immunotherapy drugs and pharmaceutical companies
Thorough review of tumor antigen discovery, immunomodulating strategies and adjuvants
Thorough review of antibody and vaccine delivery and technologies surrounding it - The next generation
Progress analysis of six major cancer vaccine indications and late stage antibody development projects, including players, drugs, clinical progress and pitfalls